180 related articles for article (PubMed ID: 24502396)
1. Establishment of monoclonal anti-human CD26 antibodies suitable for immunostaining of formalin-fixed tissue.
Hatano R; Yamada T; Matsuoka S; Iwata S; Yamazaki H; Komiya E; Okamoto T; Dang NH; Ohnuma K; Morimoto C
Diagn Pathol; 2014 Feb; 9():30. PubMed ID: 24502396
[TBL] [Abstract][Full Text] [Related]
2. Development of novel monoclonal antibodies with specific binding affinity for denatured human CD26 in formalin-fixed paraffin-embedded and decalcified specimens.
Hatano R; Yamada T; Madokoro H; Otsuka H; Komiya E; Itoh T; Narita Y; Iwata S; Yamazaki H; Matsuoka S; Dang NH; Ohnuma K; Morimoto C
PLoS One; 2019; 14(6):e0218330. PubMed ID: 31194830
[TBL] [Abstract][Full Text] [Related]
3. Nuclear localization of CD26 induced by a humanized monoclonal antibody inhibits tumor cell growth by modulating of POLR2A transcription.
Yamada K; Hayashi M; Madokoro H; Nishida H; Du W; Ohnuma K; Sakamoto M; Morimoto C; Yamada T
PLoS One; 2013; 8(4):e62304. PubMed ID: 23638030
[TBL] [Abstract][Full Text] [Related]
4. A method to generate antigen-specific mAb capable of staining formalin-fixed, paraffin-embedded tissue sections.
Wang X; Campoli M; Cho HS; Ogino T; Bandoh N; Shen J; Hur SY; Kageshita T; Ferrone S
J Immunol Methods; 2005 Apr; 299(1-2):139-51. PubMed ID: 15896802
[TBL] [Abstract][Full Text] [Related]
5. [Development of New Therapy for Malignant Mesothelioma Based on CD26 Molecule].
Morimoto C; Ohnuma K
Gan To Kagaku Ryoho; 2016 Jul; 43(7):855-62. PubMed ID: 27431629
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of CD26/DPPIV in mesothelioma tissue and mesothelioma cell lines.
Amatya VJ; Takeshima Y; Kushitani K; Yamada T; Morimoto C; Inai K
Oncol Rep; 2011 Dec; 26(6):1369-75. PubMed ID: 21894438
[TBL] [Abstract][Full Text] [Related]
7. Prevention of acute graft-versus-host disease by humanized anti-CD26 monoclonal antibody.
Hatano R; Ohnuma K; Yamamoto J; Dang NH; Yamada T; Morimoto C
Br J Haematol; 2013 Jul; 162(2):263-77. PubMed ID: 23692598
[TBL] [Abstract][Full Text] [Related]
8. Correlation of the epitopes defined by anti-CD26 mAbs and CD26 function.
Dong RP; Tachibana K; Hegen M; Scharpé S; Cho D; Schlossman SF; Morimoto C
Mol Immunol; 1998 Jan; 35(1):13-21. PubMed ID: 9683260
[TBL] [Abstract][Full Text] [Related]
9. The adenosine deaminase-binding region is distinct from major anti-CD26 mAb epitopes on the human dipeptidyl peptidase IV(CD26) molecule.
Hühn J; Olek S; Fleischer B; von Bonin A
Cell Immunol; 1999 Feb; 192(1):33-40. PubMed ID: 10066344
[TBL] [Abstract][Full Text] [Related]
10. G1/S cell cycle arrest provoked in human T cells by antibody to CD26.
Ohnuma K; Ishii T; Iwata S; Hosono O; Kawasaki H; Uchiyama M; Tanaka H; Yamochi T; Dang NH; Morimoto C
Immunology; 2002 Nov; 107(3):325-33. PubMed ID: 12423308
[TBL] [Abstract][Full Text] [Related]
11. [Antibody therapy for malignant mesothelioma: humanized anti-cD26 mAb therapy].
Morimoto C; Ohnuma K
Nihon Rinsho; 2012 Dec; 70(12):2177-82. PubMed ID: 23259393
[TBL] [Abstract][Full Text] [Related]
12. Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors.
Inamoto T; Yamada T; Ohnuma K; Kina S; Takahashi N; Yamochi T; Inamoto S; Katsuoka Y; Hosono O; Tanaka H; Dang NH; Morimoto C
Clin Cancer Res; 2007 Jul; 13(14):4191-200. PubMed ID: 17634548
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of YS110, a recombinant humanized monoclonal antibody to CD26, in Japanese patients with advanced malignant pleural mesothelioma.
Takeda M; Ohe Y; Horinouchi H; Hida T; Shimizu J; Seto T; Nosaki K; Kishimoto T; Miyashita I; Yamada M; Kaneko Y; Morimoto C; Nakagawa K
Lung Cancer; 2019 Nov; 137():64-70. PubMed ID: 31557561
[TBL] [Abstract][Full Text] [Related]
14. Development of murine monoclonal antibodies for the immunohistochemical diagnosis of systemic bovine aspergillosis.
Jensen HE; Halbaek B; Lind P; Krogh HV; Frandsen PL
J Vet Diagn Invest; 1996 Jan; 8(1):68-75. PubMed ID: 9026084
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of somatostatin receptor subtype expression in human neuroendocrine tumors using two sets of new monoclonal antibodies.
Lambertini C; Barzaghi-Rinaudo P; D'Amato L; Schulz S; Nuciforo P; Schmid HA
Regul Pept; 2013 Nov; 187():35-41. PubMed ID: 24188818
[TBL] [Abstract][Full Text] [Related]
16. First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers.
Angevin E; Isambert N; Trillet-Lenoir V; You B; Alexandre J; Zalcman G; Vielh P; Farace F; Valleix F; Podoll T; Kuramochi Y; Miyashita I; Hosono O; Dang NH; Ohnuma K; Yamada T; Kaneko Y; Morimoto C
Br J Cancer; 2017 Apr; 116(9):1126-1134. PubMed ID: 28291776
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of Middle East respiratory syndrome coronavirus infection by anti-CD26 monoclonal antibody.
Ohnuma K; Haagmans BL; Hatano R; Raj VS; Mou H; Iwata S; Dang NH; Bosch BJ; Morimoto C
J Virol; 2013 Dec; 87(24):13892-9. PubMed ID: 24067970
[TBL] [Abstract][Full Text] [Related]
18. Development and Characterization of a Novel Monoclonal Antibody Against Chitinase-like Protein CHID1 Applicable for Immunohistochemistry on Formalin Fixed Paraffin-Embedded Sections.
Samoilova DV; Kovaleva OV; Shelekhova KV; Petrenko AA; Kurochkin SN; Fedotov RV; Gratchev A
Monoclon Antib Immunodiagn Immunother; 2019 Feb; 38(1):12-17. PubMed ID: 30657411
[TBL] [Abstract][Full Text] [Related]
19. The costimulatory activity of the CD26 antigen requires dipeptidyl peptidase IV enzymatic activity.
Tanaka T; Kameoka J; Yaron A; Schlossman SF; Morimoto C
Proc Natl Acad Sci U S A; 1993 May; 90(10):4586-90. PubMed ID: 7685106
[TBL] [Abstract][Full Text] [Related]
20. Characterization of anti-HLA class II monoclonal antibody LGII-612.14 reacting with formalin fixed tissues.
Temponi M; Kekish U; Hamby CV; Nielsen H; Marboe CC; Ferrone S
J Immunol Methods; 1993 May; 161(2):239-56. PubMed ID: 8505553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
